CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number | Lead Group | Study Title | CIRB | Study Status |
|---|---|---|---|---|
| GOG-0219 | GOG | A Phase III; Randomized Trial of Weekly Cisplatin and Radiation Versus Cisplatin and Tirapazamine and Radiation in Stage IB2; IIA; IIB; IIIB; and IVA Cervical Carcinoma Limited to the Pelvis | Adult CIRB - Late Phase Emphasis | Completed |
| ACNS1021 | COG | A Phase II Study of Sunitinib (NSC# 736511; IND# 74019) in Recurrent; Refractory or Progressive High Grade Glioma and Ependymoma Tumors in Pediatric and Young Adult Patients | Pediatric CIRB | Completed |
| S0421 | SWOG | Phase III Study of Docetaxel and Atrasentan Versus Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer | Adult CIRB - Late Phase Emphasis | Completed |
| SWOG-9007 | SWOG | Cytogenetic Studies in Leukemia Patients | Adult CIRB - Late Phase Emphasis | Completed |
| 9874 | ETCTN | A Phase I Trial of AT13387 in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (LA-SCCHN) receiving Concurrent Radiation and Cisplatin | Adult CIRB - Early Phase Emphasis | Completed |
| N0723 | NCCTG | MARVEL: Marker Validation of Erlotinib in Lung Cancer- A Phase III Biomarker Validation Study of Second-line Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib | Adult CIRB - Late Phase Emphasis | Completed |
| 10608 | ETCTN | A Phase II Trial of Durvalumab with Gemcitabine and Cisplatin as Neoadjuvant Therapy for High-Risk Resectable Intrahepatic Cholangiocarcinoma | Adult CIRB - Early Phase Emphasis | Completed |
| RTOG-P-0011 | RTOG | Phase III Randomized Study of Adjuvant Therapy For High Risk PT2-3N0 Prostate Cancer | Adult CIRB - Late Phase Emphasis | Completed |
| CALGB-30801 | CALGB | A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer | Adult CIRB - Late Phase Emphasis | Completed |
| ADVL1522 | COG | A Phase 2 Study of IMGN901 (Lorvotuzumab Mertansine; IND# 126953; NSC# 783609) in Children with Relapsed or Refractory Wilms Tumor; Rhabdomyosarcoma; Neuroblastoma; Pleuropulmonary Blastoma; Malignant Peripheral Nerve Sheath Tumor (MPNST) and Synovial Sarcoma | Pediatric CIRB | Completed |